PharmGKB: The Pharmacogenomics Knowledge Base

  • Caroline F. Thorn
  • Teri E. Klein
  • Russ B. Altman
Part of the Methods in Molecular Biology book series (MIMB, volume 1015)


The Pharmacogenomics Knowledge Base, PharmGKB, is an interactive tool for researchers investigating how genetic variation affects drug response. The PharmGKB Web site,, displays genotype, molecular, and clinical knowledge integrated into pathway representations and Very Important Pharmacogene (VIP) summaries with links to additional external resources. Users can search and browse the knowledgebase by genes, variants, drugs, diseases, and pathways. Registration is free to the entire research community, but subject to agreement to use for research purposes only and not to redistribute. Registered users can access and download data to aid in the design of future pharmacogenetics and pharmacogenomics studies.

Key words

PharmGKB Database Pharmacogenetics Pharmacogenomics Genotype Phenotype Pathways VIP genes Pharmacogenes 



The authors would like to acknowledge Dorit Berlin, Michelle Whirl Carrillo, John Conroy, Adrien Coulet, Sean David, Katrina Easton, Ray Fergerson, Yael Garten, Li Gong, Mei Gong, Winston Gor, Joan Hebert, Tina Hernandez-Boussard, Micheal Hewett, Amy Hodge, Laura Hodges, Daniel Holbert, Tiffany Jung, Mark Kiuchi, Steve Lin, Feng Liu, Xing Jian Lou, Charity Lu, Andrew MacBride, Ellen McDonagh, Diane Oliver, Connie Oshiro, Ryan Owen, Daniel Rubin, Katrin Sangkuhl, Farhad Shafa, Ravi Shankar, Rebecca Tang, TC Truong, Ryan Whaley, Mark Woon, and Tina Zhou for their contributions to building the PharmGKB.

The PharmGKB is financially supported by NIH/NIGMS (R24GM61374).


  1. 1.
  2. 2.
    Altman RB, Klein TE (2002) Challenges for biomedical informatics and pharmacogenomics. Annu Rev Pharmacol Toxicol 42:113–133PubMedCrossRefGoogle Scholar
  3. 3.
    Povey S et al (2001) The HUGO Gene Nomenclature Committee (HGNC). Hum Genet 109:678–680PubMedCrossRefGoogle Scholar
  4. 4.
    Wishart DS et al (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34:D668–D672PubMedCrossRefGoogle Scholar
  5. 5.
    Eichelbaum M et al (2009) New feature: pathways and important genes from PharmGKB. Pharmacogenet Genomics 19:403PubMedCrossRefGoogle Scholar
  6. 6.
    Sangkuhl K et al (2008) PharmGKB: understanding the effects of individual genetic variants. Drug Metab Rev 40:539–551PubMedCrossRefGoogle Scholar
  7. 7.
    Relling MV, Klein TE (2011) CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 89:464–467PubMedCrossRefGoogle Scholar
  8. 8.
    Swen JJ et al (2011) Pharmacogenetics: from bench to byte–an update of guidelines. Clin Pharmacol Ther 89:662–673PubMedCrossRefGoogle Scholar
  9. 9.
    Bolton E, Wang Y, Thiessen PA, Bryant SH (2008) PubChem: integrated platform of small molecules and biological activities. In: Annual Reports in Computational Chemistry. American Chemical Society, Washington, DCGoogle Scholar
  10. 10.
    (US), N. L. o. M. MeSH Browser
  11. 11.
    Organisation, I. H. T. S. D. SNOMED CT
  12. 12.
    Rubin DL et al (2005) A statistical approach to scanning the biomedical literature for pharmacogenetics knowledge. J Am Med Inform Assoc 12:121–129PubMedCrossRefGoogle Scholar
  13. 13.
    Altman RB et al (2003) Indexing pharmacogenetic knowledge on the World Wide Web. Pharmacogenetics 13:3–5PubMedCrossRefGoogle Scholar
  14. 14.
    Garten Y, Altman RB (2009) Pharmspresso: a text mining tool for extraction of pharmacogenomic concepts and relationships from full text. BMC Bioinformatics 10(Suppl 2):S6PubMedCrossRefGoogle Scholar
  15. 15.
    Coulet A et al (2010) Using text to build semantic networks for pharmacogenomics. J Biomed Inform 43:1009–1019PubMedCrossRefGoogle Scholar
  16. 16.
    Chen J et al (2010) Interethnic comparisons of important pharmacology genes using SNP databases: potential application to drug regulatory assessments. Pharmacogenomics 11:1077–1094PubMedCrossRefGoogle Scholar
  17. 17.
    Sissung TM et al (2010) Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics 11:89–103PubMedCrossRefGoogle Scholar
  18. 18.
    Gamazon ER et al (2009) A pharmacogene database enhanced by the 1000 Genomes Project. Pharmacogenet Genomics 19:829–832PubMedCrossRefGoogle Scholar
  19. 19.
    Feng J et al (2010) Compilation of a comprehensive gene panel for systematic assessment of genes that govern an individual’s drug responses. Pharmacogenomics 11:1403–1425PubMedCrossRefGoogle Scholar
  20. 20.
    Demir E et al (2010) The BioPAX community standard for pathway data sharing. Nat Biotechnol 28:935–942PubMedCrossRefGoogle Scholar
  21. 21.
    Desta Z et al (2009) Antiestrogen pathway (aromatase inhibitor). Pharmacogenet Genomics 19:554–555PubMedCrossRefGoogle Scholar
  22. 22.
    Thorn CF, Klein TE, Altman RB (2009) Codeine and morphine pathway. Pharmacogenet Genomics 19:556–558PubMedCrossRefGoogle Scholar
  23. 23.
    Yang J et al (2009) Etoposide pathway. Pharmacogenet Genomics 19:552–553PubMedCrossRefGoogle Scholar
  24. 24.
    Marsh S et al (2009) Platinum pathway. Pharmacogenet Genomics 19:563–564PubMedCrossRefGoogle Scholar
  25. 25.
    Sangkuhl K, Klein TE, Altman RB (2009) Selective serotonin reuptake inhibitors pathway. Pharmacogenet Genomics 19:907–909PubMedCrossRefGoogle Scholar
  26. 26.
    Zaza G et al (2010) Thiopurine pathway. Pharmacogenet Genomics 20:573–574PubMedCrossRefGoogle Scholar
  27. 27.
    Gong L, Altman RB, Klein TE (2011) Bisphosphonates pathway. Pharmacogenet Genomics 21:50–53PubMedCrossRefGoogle Scholar
  28. 28.
    Maitland ML et al (2010) Vascular endothelial growth factor pathway. Pharmacogenet Genomics 20:346–349PubMedCrossRefGoogle Scholar
  29. 29.
    Sangkuhl K, Klein TE, Altman RB (2010) Clopidogrel pathway. Pharmacogenet Genomics 20:463–465PubMedGoogle Scholar
  30. 30.
    Sangkuhl K et al (2011) Platelet aggregation pathway. Pharmacogenet Genomics 21(8):516–521PubMedCrossRefGoogle Scholar
  31. 31.
    Oshiro C et al (2009) Taxane Pathway. Pharmacogenet Genomics 19:979–983PubMedCrossRefGoogle Scholar
  32. 32.
    Mikkelsen TS et al (2011) PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics 21(10):679–686PubMedCrossRefGoogle Scholar
  33. 33.
    Sangkuhl K, Klein TE, Altman RB (2011) PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics 21(11):769–772PubMedCrossRefGoogle Scholar
  34. 34.
    Thorn CF et al (2011) Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 21(7):440–446PubMedCrossRefGoogle Scholar
  35. 35.
    Thorn CF et al (2011) PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics 21:237–242PubMedGoogle Scholar
  36. 36.
    Sim SC, Altman RB, Ingelman-Sundberg M (2011) Databases in the area of pharmacogenetics. Hum Mutat 32:526–531PubMedCrossRefGoogle Scholar
  37. 37.
    Thorn CF, Klein TE, Altman RB (2010) Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics 11:501–505PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  • Caroline F. Thorn
    • 1
  • Teri E. Klein
    • 2
  • Russ B. Altman
    • 1
  1. 1.Department of Genetics, School of MedicineStanford UniversityStanfordUSA
  2. 2.Department of GeneticsStanford University Medical CenterStanfordUSA

Personalised recommendations